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Integration of oxygen signaling at the consensus HRE
Abstract
The hypoxia-inducible factor 1 (HIF-1) was initially identified as a transcription factor that regulated
erythropoietin gene expression in response to a decrease in oxygen availability in kidney tissue.
Subsequently, a family of oxygen-dependent protein hydroxylases was found to regulate the abundance
and activity of three oxygen-sensitive HIFalpha subunits, which, as part of the HIF heterodimer,
regulated the transcription of at least 70 different effector genes. In addition to responding to a decrease
in tissue oxygenation, HIF is proactively induced, even under normoxic conditions, in response to
stimuli that lead to cell growth, ultimately leading to higher oxygen consumption. The growing cell thus
profits from an anticipatory increase in HIF-dependent target gene expression. Growth stimuli-activated
signaling pathways that influence the abundance and activity of HIFs include pathways in which kinases
are activated and pathways in which reactive oxygen species are liberated. These pathways signal to the
HIF protein hydroxylases, as well as to HIF itself, by means of covalent or redox modifications and
protein-protein interactions. The final point of integration of all of these pathways is the
hypoxia-response element (HRE) of effector genes. Here, we provide comprehensive compilations of
the known growth stimuli that promote increases in HIF abundance, of protein-protein interactions
involving HIF, and of the known HIF effector genes. The consensus HRE derived from a comparison of
the HREs of these HIF effectors will be useful for identification of novel HIF target genes, design of
oxygen-regulated gene therapy, and prediction of effects of future drugs targeting the HIF system.
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Oxygen availability regulates many physiological and pathophysiological processes, 
including embryonic development, high-altitude adaptation, wound healing, inflammation, 
ischemic diseases and cancer. Central to the understanding of these processes is the 
elucidation of the molecular mechanisms by which cells react and adapt to insufficient 
oxygen supply (hypoxia). The last few years brought a wealth of novel insights into these 
processes. Four oxygen-sensing protein hydroxylases have been discovered which regulate 
the abundance and activity of three hypoxia-inducible transcription factors (HIFs) and thereby 
the activity of at least 70 effector genes involved in hypoxic adaptation. In addition to its 
reactive nature in response to a decrease in tissue oxygenation, it became evident that HIFs 
are also proactively induced, even under normoxic conditions, in response to growth stimuli 
which ultimately lead to higher oxygen consumption. The growing cell thus profits from an 
anticipatory increase in HIF-dependent target gene expression. Growth stimuli-activated 
signalling pathways, influencing the abundance and activity of HIFs, include kinase 
pathways, reduction-oxidation (redox)-active substances and reactive oxygen species. The 
final point of integration of all of these pathways are the hypoxia-response elements (HREs) 
of effector genes which bind the HIFs and confer the induction of gene expression.  
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Abstract 
The hypoxia-inducible factor (HIF)-1 had been discovered originally as a transcription factor 
regulating erythropoietin gene expression, reactive to a decrease in oxygen availability in 
kidney tissue. Meanwhile, four oxygen-dependent protein hydroxylases were found to 
regulate the abundance and activity of three oxygen-sensitive HIFα subunits, which in turn 
directly regulate the transcription of at least 70 different effector genes. In addition to its 
reactive nature in response to a decrease in tissue oxygenation, it became evident that HIF is 
also proactively induced, even under normoxic conditions, in response to growth stimuli 
which ultimately lead to higher oxygen consumption. The growing cell thus profits from an 
anticipatory increase in HIF-dependent target gene expression. Growth stimuli-activated 
signalling pathways, influencing the abundance and activity of HIFs, include kinase 
pathways, reduction-oxidation (redox)-active substances and reactive oxygen species (ROS). 
Knots of the network of these pathways signal to the HIF protein hydroxylases as well as to 
HIF itself, via covalent or redox modifications as well as protein-protein interactions. The 
final point of integration of all of these pathways are the hypoxia-response elements (HREs) 
of effector genes. Here, we provide comprehensive compilations of the known growth stimuli 
inducing HIF, HIF protein-protein interactions as well as of the known HIF effector genes. 
The resulting consensus HRE will be useful for the identification of novel HIF target genes, 
for the design of oxygen-regulated gene therapy as well as for the prediction of effects of 
future drugs targeting the HIF system.  
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Introduction 
Oxygen availability regulates many physiological and pathophysiological processes, 
including embryonic development, high-altitude adaptation, wound healing, inflammation, 
ischemic diseases and cancer. Central to the understanding of these processes is the 
elucidation of the molecular mechanisms by which cells react and adapt to insufficient 
oxygen supply (hypoxia). The last few years brought a wealth of novel insights into these 
processes. In particular, oxygen-sensing protein hydroxylases have been discovered which 
regulate the abundance and activity of hypoxia-inducible transcription factors and thereby the 
expression levels of effector genes involved in either anticipatory metabolic changes, adaptive 
survival or programmed death of the affected tissue (1-5).  
 
Oxygen sensing and reactive HIF regulation 
Cellular oxygen partial pressure is sensed by a family of prolyl-4-hydroxylase domain (PHD) 
enzymes that covalently modify hypoxia-inducible factor (HIF) α subunits (6-9). This family 
is comprised of three members called PHD1, PHD2, PHD3, or HIF prolyl hydroxylase (HPH) 
HPH3, HPH2, HPH1, respectively (10, 11). A fourth member, called PH-4, regulates HIF-1α 
under overexpression conditions only (12). Upon hydroxylation under normoxic conditions, 
HIFα is bound by the von Hippel-Lindau (VHL) tumor suppressor protein and targeted for 
proteasomal destruction (13). Thus, the high turnover rate of HIFα subunits allows for a very 
rapid stabilization under hypoxic conditions (14). Following a further decrease in oxygen 
availability, also the asparagine hydroxylase function of the factor inhibiting HIF (FIH) 
becomes impaired, resulting in a decrease in C-terminal HIFα hydroxylation. This allows for 
the progressively increased recruitment of p300/CPB transcriptional co-activators, leading to 
a successively higher transcriptional function of HIF (15, 16). 
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 The PHD and FIH oxygen sensors are comprised of a family of enzymes that catalyse a 
complex reaction involving oxygen, ferrous iron, 2-oxoglutarate, the substrate protein and 
probably ascorbate. Upon hydroxylation of target proteins, succinate and CO2 are released. 
Thus, protein hydroxylation is a non-reversible process and protein hydroxylases are non-
equilibrium enzymes. As a consequence, this multi-component reaction per se provides the 
possibility to integrate several signalling pathways. Indeed, it has been shown that ascorbate 
(17), transition metals (18, 19), ROS including NO (20, 21) and Krebs cycle intermediates 
(22, 23) influence the activity of the PHDs. In addition, protein-protein interactions affect the 
abundance and activity of the PHDs and FIH (Table 1).  
 Once stabilized, HIFα heterodimerizes with the constitutively expressed β subunit 
ARNT (aryl hydrocarbon receptor nuclear translocator) to form the heterodimeric 
transcription factor HIF. HIF then binds DNA at the HRE and recruits transcriptional co-
activators such as p300/CBP. Apart from these essential protein-protein interactions, a 
multitude of other proteins are known to interact with HIFα. Table 2 provides a 
comprehensive list of these interaction partners which either affect HIFα stability or 
transcriptional activity, and thus allows multiple other signalling pathways to converge into 
the oxygen-regulated HIF pathway.  
 
PHDs - far more than simple oxygen sensors 
If the only function of the HIFα prolyl-4-hydroxylases were to sense oxygen, probably an 
excess of sensory protein simply regulated by the oxygen availability would be sufficient. 
However, molecular oxygen sensing fulfils far more functions than simply measuring oxygen 
at a given threshold value:  
 First, different tissues are differently vascularized, unequally perfused and show 
spatially and temporally variable oxygen consumption rates. Thus, the mean oxygen partial 
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pressures vary from tissue to tissue and within a given tissue oxygen gradients exist from the 
nearest blood vessels towards the oxygen consuming cells. Nevertheless, every tissue is 
capable of sensing a reduction in oxygenation and adequately responds to such a reduction by 
inducing HIF-dependent gene expression. Therefore, hypoxia thresholds vary both spatially 
and temporally and the PHD oxygen sensors evolved to meet these requirements by showing 
a variable tissue-specific expression pattern (12, 24-28). How PHDs are spatially regulated 
within the oxygen gradient at the subcellular level (i.e. from the plasma membrane to the 
mitochondrial oxygen sink), and whether there exists a cellular re-direction of oxygen 
towards the PHDs under conditions of mitochondrial inhibition (29), are open questions 
which are very difficult to answer experimentally. 
 Second, every successful adaptation to hypoxia eventually results in re-oxygenation of 
the affected tissue. Because following hypoxia there are much higher levels of HIFα in the 
cell, the oxygen-dependent hydroxylation and degradation machinery must increase its 
capacity to cope with the degradation of the increased protein mass. Indeed, HIFα subunit 
induction is a transient process, even when very high exogenous HIF-1α levels are over-
expressed (30). Interestingly, PHD2 and PHD3, but not PHD1, are induced transcriptionally 
under hypoxic conditions, at least in part by HIF-dependent mechanisms (31-37).  
 Third, even if the HIF system had evolved exclusively for the adaptation of an organism 
to hypoxia, it became evident during the last few years that HIFα is induced also under 
normoxic conditions by various growth stimuli (see below). How can HIFα protein 
stabilization occur in the presence of active PHDs and sufficient oxygen supply? The answer 
lies in the fact that PHDs are not present within cells in a large excess but rather there is a fine 
balance between HIFα production and PHD-dependent degradation. If either one is 
upregulated it overcomes the function of the other. Thus, as well as an increase in PHD 
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synthesis leads to HIFα degradation, an increase in HIFα synthesis leads to its stabilization 
even under normoxic conditions. 
 
Cell growth and proactive HIF regulation 
The finely tuned balance between oxygen-dependent HIFα degradation and oxygen-
independent HIFα synthesis introduces the possibility of HIF regulation at an additional level. 
Indeed, normoxic induction by a large number of growth stimuli and other factors has been 
reported (Table 3). These stimuli can be roughly grouped by their ability to induce common 
cellular signalling pathways, mostly kinase and/or ROS pathways. Kinase pathways involved 
in HIF regulation often include the p38, p42/p44 and PI3K pathways. Intriguingly, 
stimulation of the PI3 kinase pathway by heregulin or IGF-1 has been shown to result in a 
general induction of protein translation. Because upregulation of HIFα translation can 
overcome its oxygen-dependent degradation, an apparently specific induction of HIFα can be 
observed (38, 39). These prototype experiments are likely to explain how HIFα can be 
stabilized, even under normoxic conditions, by saturation of the degradation machinery. 
 In addition to the kinase signalling pathways, numerous reports appeared about an 
involvement of ROS in HIFα protein stabilization by either growth stimuli or hypoxia. Non-
conclusive data were obtained so far about the source(s) of the ROS and whether hypoxia 
leads to an increase or decrease in ROS levels (40). However, ROS do have the potential to 
interfere with the complex process of protein hydroxylation. Indeed, the increase in ROS in 
junD-/- cells leads to a decrease in PHD activity and hence to HIF-1α accumulation (20). 
Thus, this study provides an elegant explanation for the molecular mechanism how non-toxic 
ROS levels could serve as specific signalling molecules regulating HIFs. 
 A reactive oxygen compound of particular interest is NO. It has been reported that NO 
normoxically stabilizes HIF-1α (41-44). However, contradictory reports have been published 
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showing that treatment with NO donors (as well as with CO), or ectopic expression of 
inducible NO-synthase (which is by itself a HIF-1 target), both abrogated HIF-1 activity (45-
48). This discrepancy might be explained by the finding that NO effects seem to be transient 
because initial NO treatment increased, but prolonged NO treatment decreased both HIF-1α 
protein and hypoxic EPO expression (49). Indeed, NO inhibits PHD activity (21). Thus, an 
initial increase in HIFα might be counteracted by a HIF-dependent increase in PHD 
expression levels. Moreover, NO inhibits mitochondrial respiration and might lead to the 
redistribution of O2 from mitochondria to the PHD oxygen sensors (29). It is important to 
mention that intracellular oxygen levels for technical reasons have never been measured so 
far, and an actual redistribution of O2 could not be demonstrated experimentally. However, a 
recent report showed that upon inhbition of the mitochondrial electron transport chain under 
mild hypoxic conditions (3% O2), HIF-1α stabilization is impaired in normal cell culture 
dishes but not in oxygen-permeable dishes or in severe hypoxia (0.1% O2) (50). Similar data 
were obtained in p38 kinase pathway-deficient cells where mitochondria-dependent HIF-1α 
induction is impaired in hypoxia but not in anoxia (51). These data suggest that enough 
oxygen could be re-directed towards the PHD oxygen sensors in mild hypoxia or in gas-
impermeable dishes to allow HIFα hydroxylation. But when oxygen is too rapidly 
equilibrated through the gas-permeable dishes or when hypoxia is too severe, insufficient 
amounts of oxygen are saved by mitochondrial dysfunction to allow HIFα hydroxylation and 
subsequent degradation.  
 In conclusion, the large variety of reported growth stimuli lead to the tissue-specific 
activation of only few common signalling pathways that normally result in either the 
translational induction of HIFα or the inhibition of HIFα hydroxylation. In any case, the 
normoxic induction of the HIF system is usually only of transient nature, because HIF-
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dependent PHD upregulation forms a negative feedback loop, downregulating HIFα under 
conditions of excessive oxygen supply. 
 
The consensus HRE sequence 
Once stabilized and activated, HIF binds to the consensus HRE present in oxygen-regulated 
elements of 70 known HIF target genes. Evidence was obtained by microarray experiments 
that far more than 200 HIF target genes might exist, however, not all of them are likely to be 
regulated directly by a HRE in their regulatory regions. In this review, the actual HIF DNA-
binding site is referred to as HBS. It should be noted that a single HBS is necessary but not 
sufficient for efficient hypoxic gene activation. While the HBS is the minimal DNA domain 
required for the interaction with HIF, a fully functional HRE usually contains also 
neighbouring DNA-binding sites for additional transcription factors. These elements are not 
necessarily hypoxia-inducible but they might amplify the hypoxic response or confer tissue-
restricted activity to a HRE. Examples include HIF-1 cooperation with the ATF-1/CREB-1 
factor in the lactate dehydrogenase A gene (52, 53) or with AP-1 binding factors in the VEGF 
gene (54). Alternatively, multimerization of HBS can also form a functional HRE. Two or 
three adjacent HBSs were found for example in the genes encoding transferrin, several 
glycolytic enzymes, glucose transporter-1 etc. Table 4 provides a comprehensive overview of 
the 70 known HIF-dependent target genes. Figure 1 summarizes the nucleotide frequency at a 
given position based on the 107 HREs listed in Table 4. 
 The resulting mandatory core consensus HBS sequence within the HRE is CGTG with 
variable occurrence especially of the 5' flanking bases. To determine the expected frequencies 
for each nucleotide position, mean values of the apparently randomly distributed 3' flanking 
positions +6 to +12 (Figure 1) were calculated. Apart from the core HBS CGTG, several other 
nucleotide positions show a non-random distribution when compared to these mean values. 
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Most important is the prevalence of A at the -1 position which deviates 4.5-fold from the 
expected frequency. The second most important site appears to be the -3 position which 
shows a 4.2-fold underrepresentation of T. Positions -5 and -2 show a 2.0- and 1.8-fold 
underrepresentation of T and A, respectively, and position +5 reveals a 1.7-fold 
overrepresentation of C (Figure 1). 
 A systematic mutational analysis of the -2 position in the context of the ACGTG core 
HRE revealed that it can confer different HRE activity under 0.5% O2 conditions with the 
preferrence T>>G>C (55). Even if the functional relevance is unknown, HIFβ/ARNT can also 
form homodimers that bind the palindromic sequence CACGTG (56). This might explain at 
least partially why this particular HRE is less hypoxically inducible. It also implies that 
HIFβ/ARNT binds the 3' GTG half-site and the respective HIFβ/ARNT interaction partner 
binds the 5' half-site. In the case of the dioxin receptor, the 5' half-site is TNG (56), whereas 
HIFα preferentially binds NAC. However, Figure 1 suggests that additional 5' nucleotides 
confer specificity and probably also activity to the HRE. In fact, we previously demonstrated 
that the occurrence of A at the -2 position is associated with a decrease in HRE activity in the 
endothelin-1 and Flt-1 genes (57). 
 It is still an open question whether and how HIF-1 and HIF-2 distinguish between target 
genes. A recent report showed that in VHL-defective cells different sets of genes are regulated 
by HIF-1 or HIF-2 (58). Only few data are available on the specific interaction of HIF-2 with 
the HBS. The VEGF receptor Flk-1 apparently is regulated specifically by HIF-2 (59). 
However, no obvious difference in the HRE composition compared to HIF-1 target genes 
could be observed (Table 4 and Figure 1). Intriguingly, even if HIF-1 had been discovered as 
the responsible transcription factor for hypoxic erythropoietin induction, it turned out that 
HIF-2 rather than HIF-1 regulates erythropoietin expression in the kidney (60, 61). Thus, 
distinction of HIF-1 vs. HIF-2 target genes does not seem to be dependent on HRE 
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composition, but rather on cooperation with other transcription factors and tissue-specific 
HIFα expression patterns. 
 Interestingly, the Myc-binding palindromic E-box CACGTG is the second most often 
found motif in human gene promoters (62). Even if HIF binding does not typically occur at 
the palindromic E-box, there are 22 out of 107 functional HREs known which consist of an E-
box (Table 4). This implies that even more HRE-containing, potential HIF target genes exist 
than so far recognized. However, there are far more potential HREs existing in mammalian 
gene promoters than actually used by HIF to regulate gene expression. So, what allows HIF to 
distinguish between functional and non-functional HREs when the sequence is identical? One 
explanation might be the occurence of a HIF-1 ancillary sequence (HAS) at the distance of 8 
bp to the HBS (63). Since the HAS is not well conserved and cannot be found in most HIF 
target genes it is likely that other transcription factors, which bind in close vicinity, co-operate 
with HIF in a tissue- und gene-specific manner. 
 
Epigenetic mechanisms regulating HIF binding to the HRE 
Apart from a requirement for transcription factor co-operation, also epigenetic effects reduce 
the large number of putative HBSs to relatively few functional HREs. Methylation of the CpG 
dinucleotide (containing 5-methylcytosine) plays an important regulatory role in mammalian 
gene expression, contributing to X-chromosome inactivation, genomic imprinting as well as 
tissue- and developmental stage-specific transcriptional regulation. CpG dinucleotides are 
underrepresented in the mammalian genome and are usually methylated if located outside of 
G+C rich so-called "CpG islands". The conserved core HBS contains a CpG dinucleotide, 
hence lowering the number of actual HREs found in the genome when compared to the 
frequency of a random tetranucleotide sequence. Methylated CpG interferes with transcription 
factor binding to DNA through both direct steric hindrance and the binding of repressor 
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proteins. Indeed, HIF binding to the HBS is blocked by 5-methylcytosine (64). Many HIF-
dependent target gene promoters thus overlap with methylation-free CpG islands, as 
confirmed by the high mean G+C content of 64.2% of the HREs listed in Table 4. Because 
HREs are usually identified experimentally by reporter gene or gel shift assays on non-
methylated bacterial or synthetic DNA, the data presented in Table 4 should be interpreted 
cautiously. Even the best in vitro HRE is worthless if its endogenous counterpart is CpG 
methylated in the chromatin. 
 It has been shown for the erythropoietin gene that CpG methylation of the 3' HRE 
abrogates both HIF DNA-binding and reporter gene activation, and that erythropoietin 
expression is inversely related to the degree of CpG methylation of the erythropoietin 3' HRE 
(64, 65). In contrast to most HIF-1 dependent genes where the HREs are located in 
methylation-free CpG islands, the erythropoietin 3' HRE is present in a locus with average 
G+C content and suppressed CpG dinucleotide frequency. Such loci are usually methylated 
and hence "silenced" in mammalian genomes. Thus, there must be a selective pressure to keep 
this site methylation-free. This could be the constitutive binding of a transcription factor to 
the HRE. Since HIF activity can only be detected under hypoxic conditions, the specific 
constitutive binding of ATF-1/CREB-1 (66, 67) to the HRE might prevent CpG methylation. 
In support of this model, in vivo footprinting showed that the HRE is also occupied in 
normoxia in the absence of HIF (68).  
 Another epigenetic modification regulating HRE accessibility might be oxidative DNA 
damage caused by ROS. Intriguingly, hypoxically induced ROS mediate oxidative base 
modifications of specific DNA sequences within the HIF target gene VEGF. The most 
frequently modified nucleotide is the terminal guanine of the VEGF HRE (ACGTGGG). 
Abasically modified HREs are associated with higher levels of HIF-1 and Ref-1/Ape1 
transcription factors, leading to increased reporter gene expression (69). Another hot spot for 
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oxidative DNA damage was detected in the HRE of the HIF target gene PGK1 (70). A 
selectivity for the sequence RTGR (where R is G or A) has been suggested to result from 
sequence-specific Fe2+ association and subsequent localized Fenton reaction with H2O2 
(71).Taken together, these results suggest another way how oxygen-dependent ROS 
production might signal to the HRE. Because the base modifications occur closely to but not 
directly at the conserved HBS, different HREs are likely to be unequally affected by ROS, 
providing a means of variable gene-specific transcriptional induction efficiency. 
 
Conclusion 
Figure 2 provides a simplified scheme on the most important oxygen-dependent and oxygen-
independent signalling pathways integrated in HIF-regulated gene expression as discussed in 
this review. The availability of a consensus HRE and the profound knowledge of its 
regulation will be helpful for at least two therapeutical strategies: First, the HRE is used to 
amplify gene therapy efficiencies whenever a hypoxic tissue is targeted with HRE-driven 
expression vectors (72). Second, good knowledge of the HRE sequence is essential for the 
development of drugs that specifically target endogenous HRE sequences to impair target 
gene expression such as VEGF expression (73). 
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HIF-1/2/3α transcription factors (with PHD1/2/3) (10, 11) 
TRiC chaperonin (with PHD3) (74) 
Siah1a/2 E3 ubiquitin ligases (with PHD1/3) (75) 
OS-9 (with PHD2/3) (76) 
 
HIF activity  
HIF-1/2/3α (with FIH) (15, 77, 78) 
ING4 candidate tumor suppressor (with PHD2) (79) 
VHL (with FIH) (15) 
 
 47 





PHD1/HPH3 (prolyl hydroxylation) (10, 11) 
PHD2/HPH2 (prolyl hydroxylation) (10, 11) 
PHD3/HPH1 (prolyl hydroxylation) (10, 11) 
FIH (asparaginyl hydroxylation) (15, 77) 
VHL (ubiquitination) (13) 
VLP (dom.-neg. VHL homolog) (80) 
VDU2 (deubiquitination) (81) 
ARD1 (acetylation) (82) 
PSMA7 (proteasomal degradation) (83) 
HSP90 (folding/stability) (84-87) 
HSP70 (folding/stability) (88) 
p53 (protein stability) (89, 90) 
Mdm2 (protein stability) (91, 92) 
Jab1/CSN5 (protein stability) (93, 94) 
SUMO-1 (protein stability?/TA activity?) (95) 
OS-9 (protein stability) (76) 
p42/p44 ERK (phosphorylation) (96) 
GSK-3 (phosphorylation) (97) 
DNA-PKcs, Ku70 and Ku80 (phosphorylation) (98) 
Per1 (circadian rhythm) (99) 
ERα (ERα protein stability) (100) 
 
Transcriptional co-factors 
ARNT (heterodimerization) (101-103) 
CBP/p300 (histone acetyltransferases; co-activators) (52, 104-108) 
SRC-1 (histone acetyltransferase; via CBP) (107, 109) 
TIF2 (histone acetyltransferase) (107) 
HDAC7 (histone deacetylase; co-activator) (110) 
HDAC1, 2, 3 (histone deacetylases; via VHL and FIH) (15) 
Ref-1 (redox factor) (107, 111) 
HNF4 (gene-specificity) (112, 113) 
Smad3 (gene-specificity) (114, 115) 
STAT3 (gene-specificity) (116) 
C/EBPα (gene-specificity) (117) 
Ets-1 (gene-specificity; Flk-1; HIF-2α-specific) (59) 
Myc (counteracted by HIF-1α) (118) 
p14ARF (nucleolar sequestration)  (119) 
HBx (CBP recruitment) (120) 
Brm (chromatin remodelling) (121) 
Brg-1 (chromatin remodelling) (121) 
TRIP230 (ARNT interactor; co-activator) (122) 
pRB (HIF activator) (123) 
NEMO (HIF2-α-specific) (124) 
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IGF-1 (39, 125, 126) 
IGF-2 (126) 
bFGF (130) (131) 




Il-1β (128, 135, 136) 
TNF-α (135, 137) 
Angiotensin II (130, 138) 
Endothelin-1 (139) 
Thrombin (130, 140) 
Heregulin (38) 
Nur77 (141) 




Thyroid hormone (144) 
Acetylcholine (145, 146) 
FSH (147) 
Serotonin (130) 
NO (43, 49, 148) 




Epstein-Barr virus (150) 
Hepatitis B Virus (151) 
















H+ (pH) (162) 
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Table 4. Compilation of the known HIF target genes. Only those genes were included where binding 
of HIF to the target DNA sequence in a DNA binding (DB) assay and/or functional transactivation (TA) 
of reporter gene expression have been shown. FS, flanking sequence; IVS, intervening sequence; UT, 
untranslated region. For abbreviations of gene names refer to the references. 
 
 
HRE Location Hypoxia-inducible gene Species DB TA Reference  
Oxygen supply 
gccctACGTGctgtctca 3’FS +3065/+3082 erythropoietin (erythropoiesis) human + + (163) 
gccctACGTGctgcctcg 3’FS +359/+376 erythropoietin (erythropoiesis) mouse + + (164) 
tgcagACGTGcgtgtggg 5’FS -163/-180 erythropoietin (erythropoiesis) human + + (165) 
tttgtACGTGattgctgt 5’FS -252/-269 globin-2 (O2 transport) water flea + + (166) 
ggcctACGTGatgatagc 5’FS -101/-118 globin-2 (O2 transport) water flea + + (166) 
gagggGCGTGtctctgcc 5’FS -103/-86 ferrochelatase (heme synthesis) human + + (167) 
aggacACGTGtgcgcttt 5’FS -121/-104 BCRP (heme binding) human + + (168) 
gaaatACGTGcgctttgt 5’FS -201/-184 transferrin (iron transport) human + + (169) 
tgtgtACGTGcaggaaag 5’FS -185/-168 transferrin (iron transport) human + + (169) 
agcgtACGTGcctcagga 5’FS -93/-76 transferrin receptor (iron transport) human + + (170, 171) 
tctgtACGTGaccacact 5’FS -3639/-3544 ceruloplasmin (iron oxidase) human + + (172) 
tgcatACGTGggctccaa 5’FS -978/-961 VEGF (angiogenesis) human + + (173, 174) 
tgcatACGTGggcttcca 5’FS +61/+78 VEGF (angiogenesis) rat + + (175) 
gaacaACGTGgaattagt 5’FS +1408/+1425 Flt-1/VEGF-R1 (angiogenesis) m/(h) - + (176) 
agtggGCGTGggaaaccg 5’FS -124/-107 Flk-1/VEGF-R2 (angiogenesis; HIF-2!) mouse + + (59) 
tagcgACGTGccgggcgg 5’FS -111/-128 leptin (metabolism and angiogenesis) human + + (177, 178) 
tgactACGTGctgcctag 5’FS -229/-212 iNOS (vessel diameter) mouse + + (179, 180) 
cgtgtACGTGtgtatgtg 5’FS -5375/-5358 eNOS (vessel diameter) human + + (181) 
tgtgtGCGTGtacgtgtg 5’FS -5381/-5364 eNOS (vessel diameter) human + + (181) 
agcggACGTGctggcgtg 5’FS +322/+339 heme oxygenase 1 (vessel diameter) mouse + + (182) 
agaggACGTGccacgcca 5’FS +350/+333 heme oxygenase 1 (vessel diameter) mouse + + (182) 
aggcaACGTGcagccgga 5’FS -114/-131 endothelin-1 (vessel diameter) h/(r) + + (183) 
aggcgACGTGctgccggg 5’FS -169/-151 α1B-adrenergic rec. (vessel diameter) rat + + (184) 
ggcaaACGTGttcgaact 5’FS -1106/-1089 adrenomedullin (vessel diameter) mouse + + (185, 186) 
gggacACGTGtgtgtacg 5’FS -156/-173 PAI-1 (blood flow) rat + + (187) 
tgtgtACGTGtgtaagag 5’FS -202/-185 PAI-1 (blood flow) human + + (188) 
tggagACGTGcagagcat 5’FS -1775/-1758 ANP (blood volume) rat + + (189) 
 
Cellular metabolism 
ggcgtACGTGctgcaggc IVS1 +346/+363 phosphofructokinase L (glycolysis) mouse + + (165) 
ctcggACGTGactcggac 5’FS -184/-201 aldolase A (glycolysis) human + + (190) 
tcttcACGTGcggggacc IVS4 +124/+141 aldolase A (glycolysis) human + - (165) 
gagctACGTGcgcccgta 5’FS -115/-132 GAPDH (glycolysis)  human + + (191) 
tcggtGCGTGcccagttg 5’FS -212/-195 GAPDH (glycolysis) human - + (192) 
accgaGCGTGtgggcccc 5’FS -208/-225 GAPDH (glycolysis) human - + (192) 
gccggACGTGacaaacgg 5’FS -206/-189 phosphoglycerate kinase 1 (glycolysis) human + - (190) 
gtgagACGTGcggcttcc 5’FS -173/-190 phosphoglycerate kinase 1 (glycolysis) human + + (165) 
tgccgACGTGcgctccgg 5’UT +30/+13 phosphoglycerate kinase 1 (glycolysis) human + - (165) 
tcgcgTCGTGcaggacgt 5’FS -226/-209 phosphoglycerate kinase 1 (glycolysis) mouse + - (193) 
gcaggACGTGacaaatgg 5’FS -217/-200 phosphoglycerate kinase 1 (glycolysis) mouse + + (164) 
gtgagACGTGctacttcc 5’FS -184/-201 phosphoglycerate kinase 1 (glycolysis) mouse + - (193) 
gggccACGTGcgccgcct 5’FS -590/-607 enolase 1 (glycolysis) human + - (165) 
gccggACGTGgggcccca 5’FS -413/-396 enolase 1 (glycolysis) human + - (190) 
tgagtGCGTGcgggactc 5’FS -386/-369 enolase 1 (glycolysis) human + + (190) 
ggagtACGTGacggagcc 5’FS -368/-351 enolase 1 (glycolysis) human + + (190) 
cctacACGTGggttcccg 5’FS -89/-72 lactate dehydrogenase A (glycolysis) mouse + + (53) 
agcggACGTGcgggaacc 5’FS -62/-79 lactate dehydrogenase A (glycolysis) mouse + + (53) 
accccACGTGgttctttg 5’FS -91/-74 glucokinase (glycolysis) rat + + (194) 
gcgggACGTGacgcacgt 5’FS -1293/-1276 PFKFB3 (glycolysis) human + + (195, 196) 
gacgcACGTGtggcagcc 5’FS -1284/-1267 PFKFB3 (glycolysis) human + + (195, 196) 
ttcacGCGTGccgctgct 5’FS -433/-416 PFKFB4 (glycolysis) human - + (197) 
ccaaaCCGTGctgaccat 5’FS -146/-129 PEPCK (gluconeogenesis) rat + + (198) 
cacagGCGTGccgtctga 5’FS +273/+290 glucose transporter 1 (glucose uptake) mouse + + (193, 199) 
ctgatGCGTGtcagacgg 5’FS +300/+283 glucose transporter 1 (glucose uptake) mouse + + (193) 
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gctgtACGTGcattggaa 5’FS -9/-26 CAIX (pH-regulation) human + + (200) 
tgtggACGTGggaggcgg 5’FS -198/-215 GPx-3 (glutathione peroxidase) human - + (201) 
cagtcACGTGgggggaac 5’FS -2201/-2184 CYP4B1 (eicosanoid synthesis) rabbit + + (202) 
ctcccACGTGggtgcagg 5’FS -835/-818 CYP3A6 (xenobiotic metabolism) rabbit + - (203) 
gggccACGTGagccacag 5’FS +749/+766 CYP2C11 (xenobiotic metabolism) rat + - (204) 
cagacACGTGtcaatgca 5’FS +967/+984 CYP2C11 (xenobiotic metabolism) rat + - (204) 
ccgggGCGTGggctgagc 5’FS 1020/1037 MDR1 (xenobiotic transporter) human + - (205) 
 
Cell growth and apoptosis 
caactACGTGctctggtt IVS1 +669/+652 IGFBP-1 (growth factor) human - + (206) 
gcaggACGTGctctggga IVS1 +710/+727 IGFBP-1 (growth factor) human - + (206) 
tgcccACGTGctggcaag IVS1 +928/+911 IGFBP-1 (growth factor) human - + (206) 
aggacACGTGgagaggct 5’FS -6280/-6263 TGF-β3 (placenta development) mouse + + (207) 
tcggaACGTGggccttgg 5’FS -5200/-5217 TGF-β3 (placenta development) mouse + + (207) 
aggctGCGTGcgctggtc 5’FS -89/-72 TGF-β3 (placenta development) human + + (208) 
tgtccACGTGggggcctg 5’UT +348/+331 endoglin (TGF-β co-receptor) human + + (209) 
gtggaACGTGactcaaag 5’FS -3736/-3753 CTGF (connective tissue growth factor) human + + (210) 
tctttGCGTGtgtgtgtg 5’FS -1549/-1566 CTGF (connective tissue growth factor) human + + (210) 
ggagtACGTGggcctgtg 5’FS -133/-116 ITF (intestinal barrier function) human + - (211) 
aaaacCCGTGcctcgaat 5’FS -377/-360 CD73 (intestinal barrier function) human - + (212) 
gctgtACGTGagctccgg 5’FS +265/+248 RORα4 (RA-related orphan rec.) mouse + + (213) 
tgcgaACGTGcgcccggt 5’FS -450/-433 RTP801/REDD1 (cell growth) mouse + - (214) 
cagggACGTGtccccagg 5’FS -1243/-1226 SDF-1 (CXCL12 chemokine) human - + (215) 
gaggcGCGTGcgtcgcga 5’FS -1292/-1309 CXCR4 (chemokine receptor) human + + (216) 
accccGCGTGcggtcacg 5’FS -220/-203 Nur77 (orphan steroid receptor) mouse + + (217) 
ctgcaGCGTGaccgcacg 5’FS -197/-214 Nur77 (orphan steroid receptor) mouse + + (217) 
agcgcGCGTGtgggaagg 5’FS +142/+159 met (protooncogene) human - + (218) 
agcgcGCGTGtggtcctt 5’FS +342/+359 met (protooncogene) human - + (218) 
agagcACGTGgcgggcca 5’FS -222/-205 Wt1 (Wilms' tumor suppressor) mouse + + (219) 
ttcccACGTGgcggaggg 5’FS -169/-152 TERT (telomerase) human + + (220, 221) 
tgcgcACGTGggaagccc 5’UT +40/+57 TERT (telomerase) human + + (220, 221) 
gccgcACGTGccgcacgc 5’FS -238/-221 NIP3 (pro-apoptotic)  chi. ham. - + (222) 
gccgcACGTGccacacgc 5’FS -250/-233 BNIP3 (pro-apoptotic)  human + + (223) 
tacagGCGTGagccaccg 5’FS -1288/-1271 Noxa (pro-apoptotic) human + + (224) 
caggcGCGTGaagggcgc 5’FS -139/-122 PP5 (anti-apoptotic) human + + (225) 
tacagGCGTGcgccacca 5’FS ?/? Mcl-1 (anti-apoptotic) human + + (226) 
agaggACGTGgaagggtt 5’FS -399/-382 nucleophosmin (p53 inhibition) human - + (227) 
 
Others 
tgtgcGCGTGgtgccata 5’FS -1197/-1184 Cited2/p35srj (transcriptional co-factor) human + + (228) 
acgggACGTGcagctacg 5’FS -1180/-1167 Cited2/p35srj (transcriptional co-factor) human + + (228) 
cagctACGTGcccacctc 5’FS -1170/-1157 Cited2/p35srj (transcriptional co-factor) human + + (228) 
cgaatGCGTGcgtgggtg 5’FS -729/-712 ID2 (transcriptional repressor) human + + (229) 
cacatACGTGccacagtg 5’FS -1884/-1891 ID2 (transcriptional repressor) human + + (229) 
acaggACGTGaggcatgt 5’FS -336/-353 ETS-1 (transcription factor) human + + (230) 
gccagACGTGcctggagt 5’FS -461/-444 DEC1 (transcription factor) human + + (231) 
agctcACGTGcggaacgt 5’FS -297/-314 DEC2 (transcription factor) human + + (231) 
gacgcGCGTGccctgtgg 5’FS -277/-260 DEC2 (transcription factor) human + + (231) 
agagtACGTGctag???? 5’FS -101/-114 retrotransposon VL30 rat + + (232) 
tggagACGTGcgcgtcct 5’FS -235/-218 human Herpesvirus 8 ORF34 viral + + (233) 
ggttgACGTGccactaag 5’FS -321/-338 B19 erythrovirus viral + - (234) 
tctagACGTGacccaggg 5’UT -5/+13 CD18 (leukocyte adhesion) human - + (235) 
gggggACGTGaagaaagg 5’FS -707/-690 GRP94 (chaperone) human + + (236) 
tggcaACGTGttcttcac 5’FS -403/-420 GRP94 (chaperone) human + + (236) 
gtcccACGTGtgaggggc 5’FS -253/-236 GRP94 (chaperone) human + + (236) 
accggGCGTGgtggctca 5’FS -868/-851 Furin (proprotein convertase) human + + (237) 
tggggACGTGgttgtttt 5’FS -121/-138 MT1 (matrix metalloproteinase) human - + (238) 
tcgctACGTGcgctcagt 5’FS -75/-92 collagen prolyl 4-hydroxylase  (I) rat + + (239) 
ggtgtACGTGcagagcgc 5’FS -417/-400  PHD2 (O2-sensing) human + + (37) 





Figure 1. The consensus HRE. Relative occurrence of the nucleotide distributions within the 
HREs listed in Table 4. Shadowed boxes indicate non-randomly distributed nucleotide 
compositions.  
 
Figure 2. Oxygen-dependent and oxygen-independent signalling pathways integrated in HIF-
regulated gene expression as discussed in this review.  
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